Dynamic MRI of solitary pulmonary nodules:: Comparison of enhancement patterns of malignant and benign small peripheral lung lesions

被引:84
作者
Kono, Rei
Fujimoto, Kiminori
Terasaki, Hiroshi
Mueller, Nestor L.
Kato, Seiya
Sadohara, Junko
Hayabuchi, Naofumi
Takamori, Shinzo
机构
[1] Kurume Univ, Sch Med, Dept Radiol, Fukuoka 8300011, Japan
[2] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[4] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 830, Japan
[5] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 830, Japan
关键词
chest; dynamic MRI; infectious disease; lung disease; oncologic imaging;
D O I
10.2214/AJR.05.1446
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this study was to compare the dynamic contrast-enhanced MRI enhancement characteristics of malignant and benign solitary pulmonary nodules. MATERIALS AND METHODS. The characteristics of 202 solitary pulmonary nodules ( diameter, 1 - 3 cm; 144 cases of primary lung cancer, 31 cases of focal organizing pneumonia, 15 tuberculomas, 12 hamartomas) were reviewed retrospectively. In all cases dynamic MR images were obtained before and 1, 2, 3, 4, 5, 6, and 8 minutes after bolus injection of gadopentetate dimeglumine. Maximum enhancement ratio, time at maximum enhancement ratio, slope of time - enhancement ratio curves, and washout ratio were assessed. Statistical analyses were performed with the Kruskal-Wallis test with Bonferroni correction, chi-square test, and receiver operating characteristic curves. RESULTS. For 122 (85%) of 144 primary lung cancers, time at maximum enhancement ratio was 4 minutes or less. For all tuberculomas and hamartomas, time at maximum enhancement ratio was greater than 4 minutes or gradual enhancement occurred without a peak time ( p < 0.0001). Lung cancers had different maximum enhancement ratios and slopes than benign lesions ( all p < 0.005). With 110% or lower maximum enhancement ratio as a cutoff value, the positive predictive value for malignancy was 92%; sensitivity, 63%; and specificity, 74%. With 13.5%/ min or greater slope as a cutoff value, sensitivity, specificity, positive predictive value, and negative predictive value for malignancy were 94%, 96%, 99%, and 74%, respectively. CONCLUSION. Dynamic contrast-enhanced MRI is helpful in differentiating benign from malignant solitary pulmonary nodules. Absence of significant enhancement is a strong predictor that a lesion is benign.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 41 条
[1]   False-negative findings for primary lung tumors on FDG positron emission tomography: Staging and prognostic implications [J].
Cheran, SK ;
Nielsen, ND ;
Patz, EF .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 182 (05) :1129-1132
[2]   Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging:: Correlation with tumor vascularity and prognosis [J].
Fujimoto, K ;
Abe, T ;
Müller, NL ;
Terasalki, H ;
Kato, S ;
Sadohara, J ;
Kono, R ;
Edamitsu, O ;
Ishitake, T ;
Hayashi, A ;
Rikimaru, T ;
Hayabuchi, N .
RADIOLOGY, 2003, 227 (03) :786-793
[3]  
FUJIMOTO K, 1993, RADIOLOGY, V189, P438
[4]   Pulmonary nodules resected at video-assisted thoracoscopic surgery: Etiology in 426 patients [J].
Ginsberg, MS ;
Griff, SK ;
Go, BD ;
Yoo, HH ;
Schwartz, LH ;
Panicek, DM .
RADIOLOGY, 1999, 213 (01) :277-282
[5]   Nuclear medicine imaging of lung cancer [J].
Goldsmith, SJ ;
Kostakoglu, L .
RADIOLOGIC CLINICS OF NORTH AMERICA, 2000, 38 (03) :511-+
[6]   Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases [J].
Goo, JM ;
Im, JG ;
Do, KH ;
Yeo, JS ;
Seo, JB ;
Kim, HY ;
Chung, JK .
RADIOLOGY, 2000, 216 (01) :117-121
[7]  
Guckel C, 1996, RADIOLOGY, V200, P681
[8]  
Gupta NC, 1996, J NUCL MED, V37, P943
[9]   SOLITARY PULMONARY NODULES - DETECTION OF MALIGNANCY WITH PET WITH 2-[F-18]-FLUORO-2-DEOXY-D-GLUCOSE [J].
GUPTA, NC ;
FRANK, AR ;
DEWAN, NA ;
REDEPENNING, LS ;
ROTHBERG, ML ;
MAILLIARD, JA ;
PHALEN, JJ ;
SUNDERLAND, JJ ;
FRICK, MP .
RADIOLOGY, 1992, 184 (02) :441-444
[10]  
Higashi K, 1998, J NUCL MED, V39, P1016